Article Information
History
- Received December 12, 2021
- Revision received April 19, 2022
- Revision received July 8, 2022
- Revision received August 23, 2022
- Revision received September 20, 2022
- Accepted September 22, 2022
- Published online January 10, 2023.
Copyright & Usage
© 2023 CMA Impact Inc. or its licensors This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/
Author Information
- Clémence Cabelguen, MD,
- Anaïs Saillard, CRT,
- Antoine Vanier, MD, PhD,
- Manuel Laslandes, MD,
- Juliette Leboucher, CRT,
- Morgane Rousselet, CRT,
- Elsa Thiabaud, CRT,
- Marie Grall-Bronnec, MD, PhD,
- Gaëlle Challet-Bouju, PhD
- From Nantes Université, CHU Nantes, UIC Psychiatrie et Santé Mentale, Nantes, France (Cabelguen, Saillard, Laslandes, Leboucher, Rousselet, Thiabaud, Grall-Bronnec, Challet-Bouju); Nantes Université, Université de Tours, CHU Nantes, CHU Tours, Institut national de la santé et de la recherche médicale, SPHERE, Nantes, France (Vanier, Grall-Bronnec, Challet-Bouju); and the Pharmaceutical Drugs Assessment Department, Assessment and Access to Innovation Direction, Haute Autorité de Santé, Saint-Denis, France (Vanier)
- Correspondence to: G. Challet-Bouju, UIC Psychiatrie et Santé Mentale, CHU Nantes – Hôpital St Jacques, 85 rue Saint-Jacques, 44 093 Nantes Cedex 1, France; gaelle.bouju{at}chu-nantes.fr
In this issue
Article tools
Respond to this article
Related Articles
Cited By...
- No citing articles found.